Search Results - "Stopeck, Alison"

Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore? by Stopeck, Alison T.

“…Bone‐targeted agents should be considered for all postmenopausal women with high‐risk, early‐stage breast cancer. Targeting the microenvironment and normal…”
Get full text

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study by Stopeck, Alison T, Lipton, Allan, Body, Jean-Jacques, Steger, Guenther G, Tonkin, Katia, de Boer, Richard H, Lichinitser, Mikhail, Fujiwara, Yasuhiro, Yardley, Denise A, Viniegra, María, Fan, Michelle, Jiang, Qi, Dansey, Roger, Jun, Susie, Braun, Ada

“…This randomized study compared denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor κ B (RANK) ligand, with zoledronic…”
Get full text

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years by Goss, Paul E, Ingle, James N, Pritchard, Kathleen I, Robert, Nicholas J, Muss, Hyman, Gralow, Julie, Gelmon, Karen, Whelan, Tim, Strasser-Weippl, Kathrin, Rubin, Sheldon, Sturtz, Keren, Wolff, Antonio C, Winer, Eric, Hudis, Clifford, Stopeck, Alison, Beck, J. Thaddeus, Kaur, Judith S, Whelan, Kate, Tu, Dongsheng, Parulekar, Wendy R

“…An additional 5 years of adjuvant aromatase-inhibitor therapy in women with early hormone-receptor–positive breast cancer resulted in longer disease-free…”
Get full text

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials by Lipton, Allan, Fizazi, Karim, Stopeck, Alison T, Henry, David H, Brown, Janet E, Yardley, Denise A, Richardson, Gary E, Siena, Salvatore, Maroto, Pablo, Clemens, Michael, Bilynskyy, Boris, Charu, Veena, Beuzeboc, Philippe, Rader, Michael, Viniegra, Maria, Saad, Fred, Ke, Chunlei, Braun, Ada, Jun, Susie

“…Abstract Background Patients with bone metastases from advanced cancer often experience skeletal-related events (SRE), which cause substantial pain and…”
Get full text

Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors by Streff, Alyssa, Chu-Pilli, Michele, Stopeck, Alison, Chalasani, Pavani

“…Background Anti-estrogen therapy is an effective intervention for preventing reoccurrence of hormone receptor-positive breast cancer in women. However, the…”
Get full text

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer by Stopeck, Alison T., Fizazi, Karim, Body, Jean-Jacques, Brown, Janet E., Carducci, Michael, Diel, Ingo, Fujiwara, Yasuhiro, Martín, Miguel, Paterson, Alexander, Tonkin, Katia, Shore, Neal, Sieber, Paul, Kueppers, Frank, Karsh, Lawrence, Yardley, Denise, Wang, Huei, Maniar, Tapan, Arellano, Jorge, Braun, Ada

“…Purpose Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the safety of prolonged therapy has not been adequately studied…”
Get full text

Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307 by Gralow, Julie R, Barlow, William E, Paterson, Alexander H G, M'iao, Jieling L, Lew, Danika L, Stopeck, Alison T, Hayes, Daniel F, Hershman, Dawn L, Schubert, Mark M, Clemons, Mark, Van Poznak, Catherine H, Dees, Elizabeth C, Ingle, James N, Falkson, Carla I, Elias, Anthony D, Messino, Michael J, Margolis, Jeffrey H, Dakhil, Shaker R, Chew, Helen K, Dammann, Kim Z, Abrams, Jeffrey S, Livingston, Robert B, Hortobagyi, Gabriel N

“…Abstract Background Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines…”
Get full text

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer by Yardley, Denise A, Weaver, Robert, Melisko, Michelle E, Saleh, Mansoor N, Arena, Francis P, Forero, Andres, Cigler, Tessa, Stopeck, Alison, Citrin, Dennis, Oliff, Ira, Bechhold, Rebecca, Loutfi, Randa, Garcia, Agustin A, Cruickshank, Scott, Crowley, Elizabeth, Green, Jennifer, Hawthorne, Thomas, Yellin, Michael J, Davis, Thomas A, Vahdat, Linda T

“…Glycoprotein NMB (gpNMB), a negative prognostic marker, is overexpressed in multiple tumor types. Glembatumumab vedotin is a gpNMB-specific monoclonal antibody…”
Get full text

Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatment by Alvarez, Folnetti A., Kaddour, Hussein, Lyu, Yuan, Preece, Christina, Cohen, Jules, Baer, Lea, Stopeck, Alison T., Thompson, Patricia, Okeoma, Chioma M.

“…Purpose Circulating blood plasma derived extracellular vesicles (BEVs) containing proteins hold promise for their use as minimally invasive biomarkers for…”
Get full text

Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study by MODI, Shanu, STOPECK, Alison T, CROPP, Gillian F, JOHNSON, Robert G, HANNAH, Alison L, HUDIS, Clifford A, GORDON, Michael S, MENDELSON, David, SOLIT, David B, BAGATELL, Rochelle, WEINING MA, WHELER, Jennifer, ROSEN, Neal, NORTON, Larry

“…This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with…”
Get full text

Response to letter to the Editors—Safety of long-term denosumab therapy by Stopeck, Alison T., Warner, Douglas J.

Get full text

Sulindac, a Nonselective NSAID, Reduces Breast Density in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors by Thompson, Patricia A, Huang, Chuan, Yang, Jie, Wertheim, Betsy C, Roe, Denise, Zhang, Xiaoyue, Ding, Jie, Chalasani, Pavani, Preece, Christina, Martinez, Jessica, Chow, H-H Sherry, Stopeck, Alison T

“…To evaluate the effect of sulindac, a nonselective anti-inflammatory drug (NSAID), for activity to reduce breast density (BD), a risk factor for breast cancer…”
Get full text

Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival by HAYES, Daniel F, CRISTOFANILLI, Massimo, BUDD, G. Thomas, ELLIS, Matthew J, STOPECK, Alison, MILLER, M. Craig, MATERA, Jeri, ALLARD, W. Jeffrey, DOYLE, Gerald V, TERSTAPPEN, Leon W. W. M

“…Purpose: We reported previously that ≥5 circulating tumor cells (CTC) in 7.5 mL blood at baseline and at first follow-up in 177 patients with metastatic breast…”
Get full text

Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer by RUGO, Hope S, STOPECK, Alison T, BAIR, Angel H, SOULIERES, Denis, JOY, Anil A, CHAN, Stephen, VERMA, Shailendra, LLUCH, Anna, LIAU, Katherine F, KIM, Sinil, BYCOTT, Paul, ROSBROOK, Brad

“…This multicenter, randomized, double-blind, phase II study assessed safety and efficacy of axitinib plus docetaxel in metastatic breast cancer (MBC). Women…”
Get full text

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease by Diel, Ingo J, Body, Jean-Jacques, Stopeck, Alison T, Vadhan-Raj, Saroj, Spencer, Andrew, Steger, Günther, von Moos, Roger, Goldwasser, François, Feng, Amy, Braun, Ada

“…Abstract Background We compared the activity of denosumab with zoledronic acid for delaying or preventing hypercalcaemia of malignancy (HCM) in patients with…”
Get full text

Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents by Lipton, Allan, Smith, Matthew R, Fizazi, Karim, Stopeck, Alison T, Henry, David, Brown, Janet E, Shore, Neal D, Saad, Fred, Spencer, Andrew, Zhu, Li, Warner, Douglas J

“…Bone antiresorptive agents can significantly reduce bone turnover markers (BTM) in patients with advanced cancer. We evaluated association of changes in BTMs…”
Get full text

Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer by Martinez, Jessica A., Wertheim, Betsy C., Roe, Denise J., Chalasani, Pavani, Cohen, Jules, Baer, Lea, Chow, H-H. Sherry, Stopeck, Alison T., Thompson, Patricia A.

“…Purpose To examine benefit of sulindac for relief of musculoskeletal symptoms (MSS) in patients stable on aromatase inhibitors (AIs). Methods Sulindac was…”
Get full text

Case report: Metastatic metaplastic breast cancer with choriocarinomatous features: Targeting the choriocarcinoma component for cure by Mehta, Krisha K, Nouvini, Rosa, Liu, Jingxuan, Wang, Yi, Stopeck, Alison

“…Breast cancer with choriocarcinomatous features (BCCF) is a rare and aggressive breast cancer. BCCF carries a poor prognosis and there is unfortunately scant…”
Get full text

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer by Cristofanilli, Massimo, Budd, G. Thomas, Ellis, Matthew J, Stopeck, Alison, Matera, Jeri, Miller, M. Craig, Reuben, James M, Doyle, Gerald V, Allard, W. Jeffrey, Terstappen, Leon W.M.M, Hayes, Daniel F

“…An automated device that separates, identifies, and enumerates epithelial cells in whole blood was used to measure levels of circulating tumor cells in women…”
Get full text

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801 by DeAngelo, Daniel J., Yu, Daohai, Johnson, Jeffrey L., Coutre, Steven E., Stone, Richard M., Stopeck, Alison T., Gockerman, Jon P., Mitchell, Beverly S., Appelbaum, Frederick R., Larson, Richard A.

“…Nelarabine (506U78) is a soluble pro-drug of 9-β-d-arabinofuranosylguanine (ara-G), a deoxyguanosine derivative. We treated 26 patients with T-cell acute…”
Get full text